EUVIMEDEUVIMED entdecken
Crossref

Dextromethorphan/Bupropion (Auvelity) for Agitation in Alzheimer’s Dementia

The Medical Letter on Drugs and Therapeutics · 22.06.2026 · 68 (1757) · 98-100

DOI: 10.58347/tml.2026.1757b ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 22.06.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Auvelity (Axsome), an extended-release fixed-dose combination of dextromethorphan and bupropion that was approved by the FDA for treatment of major depressive disorder in 2022,1 has now been approved for treatment of agitation associated with dementia due to Alzheimer's disease (AD). It is the second product to be approved in the US for this indication; the oral second-generation antipsychotic drug brexpiprazole (Rexulti) was approved in 2023.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseAuvelityCelexaNuedextaNuplazidRexultiSSRIsSeroqueladverse effectsantidepressantsantipsychoticsbrexpiprazolebupropioncitalopramdextromethorphan

Zitieren

APA

(2026). Dextromethorphan/Bupropion (Auvelity) for Agitation in Alzheimer’s Dementia. The Medical Letter on Drugs and Therapeutics, 68(1757), 98-100. https://doi.org/10.58347/tml.2026.1757b

Vancouver

Dextromethorphan/Bupropion (Auvelity) for Agitation in Alzheimer’s Dementia. The Medical Letter on Drugs and Therapeutics. 2026;68(1757):98-100. doi:10.58347/tml.2026.1757b

BibTeX
@article{euvimed2026,
  title = {Dextromethorphan/Bupropion (Auvelity) for Agitation in Alzheimer’s Dementia},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1757},
  pages = {98--100},
  doi = {10.58347/tml.2026.1757b}
}
Kostenlos starten →